GT Biopharma, Inc. GTBP · Stock Open GT Biopharma, Inc. in new tab
GT Biopharma, Inc. Analysis (GTBP)
Is GT Biopharma, Inc. a good investment? GT Biopharma, Inc. (GTBP) is currently trading at 7.18 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.06. This relatively low multiple may signal that GT Biopharma, Inc. is undervalued compared to historical market norms.
Earnings Schedule: GT Biopharma, Inc. is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -10.80.
Investor FAQ
Does GT Biopharma, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is GT Biopharma, Inc.?
GT Biopharma, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of 111.87.
Company Profile
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
| Split Date | Split Ratio to 1 |
|---|---|
| Feb. 11, 2021 | 0.06 |
| Feb. 5, 2024 | 0.03 |
| Sept. 8, 2026 | 1:25 |
Community Discussion